Siga Technologies Inc. (SIGA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
SIGA Technologies, Inc. (SIGA) Q3 2025 Earnings Call Transcript
SIGA Technologies, Inc. ( SIGA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diem Nguyen - CEO & Director Daniel Luckshire - Executive VP, CFO & Secretary Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Presentation Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.
SIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA News
SIGA's investment thesis is overwhelmingly tied to the renewal of the BARDA contract, which remains highly uncertain due to political and budgetary risks. Recent revenue growth and a strong balance sheet are positives, but the company faces label risk in the EU and heavy reliance on U.S. government funding. Potential catalysts include TPOXX label expansion for post-exposure prophylaxis and a new BARDA contract, while EU label changes and U.S. defunding are key risks.
SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Daniel J. Luckshire - Executive VP, CFO & Secretary Diem Nguyen - CEO & Director Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Operator Welcome to the SIGA Business Update Call.
Siga Technologies Inc. (SIGA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Siga Technologies Inc. ever had a stock split?
Siga Technologies Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Diem Nguyen CEO | NASDAQ (NMS) Exchange | 826917106 CUSIP |
| US Country | 46 Employees | 29 Apr 2025 Last Dividend | - Last Split | 9 Sep 1997 IPO Date |
Overview
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company with a specific focus on health security markets within the United States. Incorporated in 1995, the company has established its headquarters in New York, New York. SIGA Technologies is dedicated to the development, manufacture, and commercialization of solutions for serious conditions and diseases that affect health security. The core mission of SIGA revolves around enhancing preparedness and response capabilities against biological threats, thereby contributing significantly to public health defense mechanisms.
Products and Services
TPOXX (tecovirimat)
SIGA Technologies' flagship product is TPOXX, an antiviral medication that is taken orally. TPOXX has been specifically developed for the treatment of human smallpox disease caused by the variola virus. This drug represents a significant advancement in the field of biodefense, offering a critical tool in the event of a smallpox outbreak. Its approval and availability highlight SIGA’s pivotal role in enhancing national and global preparedness against potential bioterrorism or naturally occurring outbreaks of this deadly virus.
Contact Information
